2 hours ago
1
David Moadel
Mon, April 20, 2026 astatine 9:40 AM CDT 5 min read
-
Hims & Hers (HIMS) shares surged connected FDA peptide tailwinds and a Novo Nordisk concern to administer branded Wegovy, giving the institution leverage successful the GLP-1 marketplace beyond compounded alternatives.
-
Hims & Hers is accelerating is superior spending connected manufacturing infrastructure and the Eucalyptus acquisition portion expecting Q1 EPS to diminution 70% year-over-year, creating hostility betwixt the HIMS banal buyers and sellers.
-
The expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks. Get them present FREE.
Hims & Hers Health (NYSE:HIMS) shares are up 9% successful aboriginal trading Monday, climbing from $28.82 to $31 and alteration arsenic investors heap into the banal up of a May 11 net report. The determination caps a stunning week: HIMS banal has surged 49% successful the past 5 trading sessions, making it 1 of the market's astir explosive movers heading into a quarterly print.
Two catalysts are driving the enthusiasm. Renewed FDA involvement successful peptide drugs has reignited optimism astir Hims & Hers' evolving merchandise pipeline, and a favorable woody with Novo Nordisk (NYSE:NVO) has fixed bulls a factual concern communicative to rally around. The banal remains down 3% year-to-date, truthful immoderate of this week's determination looks similar a betterment trade. Yet, the velocity of the run-up raises a just question: has the marketplace gotten up of itself earlier we spot the existent numbers?
The narration betwixt Hims & Hers and Novo Nordisk has been thing but smooth. The institution reported progressive discussions with Novo Nordisk to administer Wegovy injections and oral Wegovy done its level arsenic of Q3 2025, though it cautioned that nary definitive statement whitethorn ever beryllium executed. A favorable woody present successful spot changes that calculus meaningfully.
READ: The expert who called NVIDIA successful 2010 just named his apical 10 AI stocks
Why does this substance truthful much? Hims & Hers has built implicit 1 cardinal quadrate feet of U.S. installation abstraction and has been constructing sterile injectable capableness specifically for value nonaccomplishment and hormonal support. Pairing that infrastructure with branded Wegovy organisation would springiness the institution a legitimate, differentiated presumption successful the GLP-1 marketplace alternatively than relying solely connected compounded alternatives. For investors watching the compounding regulatory risk, a Novo Nordisk narration is simply a meaningful hedge.
Novo Nordisk itself is navigating a unsmooth patch. NVO shares are down 21% year-to-date, pressured by pricing headwinds and compounding competition. A telehealth organisation concern helps Novo Nordisk scope patients directly, which explains wherefore some sides person a strategical inducement to marque thing work.
English (CA) · 
English (US) · 
Spanish (MX) ·